BIOHAVEN PHARMACTL HLDG CO L's ticker is BHVN and the CUSIP is G11196105. A total of 226 filers reported holding BIOHAVEN PHARMACTL HLDG CO L in Q1 2021. The put-call ratio across all filers is 1.62 and the average weighting 0.7%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2022 | $1,631,000 | -44.5% | 10,786 | -46.6% | 0.02% | -35.5% |
Q2 2022 | $2,941,000 | +116.2% | 20,182 | +76.0% | 0.03% | +210.0% |
Q1 2022 | $1,360,000 | -49.9% | 11,468 | -41.7% | 0.01% | -33.3% |
Q4 2021 | $2,712,000 | -2.4% | 19,678 | -1.7% | 0.02% | +15.4% |
Q3 2021 | $2,780,000 | +207.9% | 20,014 | +115.1% | 0.01% | +225.0% |
Q2 2021 | $903,000 | +49.5% | 9,305 | +5.3% | 0.00% | +33.3% |
Q1 2021 | $604,000 | -33.8% | 8,833 | -17.1% | 0.00% | -40.0% |
Q4 2020 | $913,000 | +0.4% | 10,656 | -23.8% | 0.01% | -16.7% |
Q3 2020 | $909,000 | +60.9% | 13,983 | +80.9% | 0.01% | +20.0% |
Q2 2020 | $565,000 | -44.3% | 7,731 | -74.1% | 0.01% | -50.0% |
Q1 2020 | $1,015,000 | +732.0% | 29,828 | +1236.4% | 0.01% | +900.0% |
Q4 2019 | $122,000 | -78.8% | 2,232 | -80.1% | 0.00% | -80.0% |
Q1 2019 | $576,000 | +13.6% | 11,196 | -18.3% | 0.01% | +25.0% |
Q4 2018 | $507,000 | +165.4% | 13,697 | +183.8% | 0.00% | +100.0% |
Q2 2018 | $191,000 | – | 4,826 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
RP Management, LLC | 2,111,111 | $144,294,000 | 54.16% |
Knoll Capital Management, LLC | 856,844 | $58,565,000 | 38.16% |
ORACLE INVESTMENT MANAGEMENT INC | 2,123,271 | $145,126,000 | 21.73% |
KINGDON CAPITAL MANAGEMENT, L.L.C. | 860,261 | $58,799,000 | 6.01% |
ARS Investment Partners, LLC | 561,442 | $38,375,000 | 4.46% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 176,400 | $12,057,000 | 3.19% |
Eventide Asset Management | 2,015,000 | $137,725,000 | 2.04% |
Avidity Partners Management LP | 1,049,800 | $71,754,000 | 1.98% |
SILVERARC CAPITAL MANAGEMENT, LLC | 50,089 | $3,424,000 | 1.87% |
Nicholas Investment Partners, LP | 375,654 | $25,676,000 | 1.79% |